RTOG 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer

Wong, Stuart J.; Winter, K.; Anne, Rani; Kachnic, Lisa A.; Rashid, Asma; Watson, James C.; Mitchell, Edith P.; Pollock, Jondavid; Lee, R. J.; Willett, Christopher

doi:10.1200/jco.2008.26.15_suppl.4021

Cited by 13 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results, 9% pCR, are therefore in the range of published data after CAPOX or CAPIRI therapies. Indeed the RTOG randomized trial, suggested a benefit of CAPOX vs CAPIRI in terms of pCR (21% vs 10%) with a similar pattern of toxicity [27]. The second approach is to apply neoadjuvant chemotherapy before CRT doublets.…”

Section: Discussionmentioning

confidence: 96%

Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Other recent studies using molecular targeted drugs are listed in Table 3 and have included phase I, phase II, and random phase II trials. [65][66][67][68][69][70][71][72][73][74][75][76] Some studies have shown pathological complete response rates as high as 32%. Further clinical trials are needed to confi rm the effi cacy of these regimens in the future.…”

Section: Radiotherapy Combined With Molecular Targeted Drugsmentioning

confidence: 98%

Chemoradiotherapy and adjuvant chemotherapy for rectal cancer

Watanabe

2008

Int J Clin Oncol

View full text Add to dashboard Cite

Local recurrence is an important factor in determining the outcome of patients after surgery for rectal cancer, and various attempts have been made to reduce the local recurrence rate. Randomized controlled trials have shown that radiotherapy combined with total mesorectal excision can reduce the local recurrence rate in rectal cancer patients who undergo curative surgery. Chemoradiotherapy is more effective in achieving local control than radiotherapy alone, and preoperative chemoradiotherapy is superior to postoperative chemoradiotherapy in terms of adverse events. Recent advances have led to the identification of potential therapeutic targets such as epidermal growth factor receptor, vascular endothelial growth factor, and endothelial receptors. These new agents have been used in combination with conventional chemoradiotherapy, and higher pathological complete response rates have been reported for such combinations in comparison with conventional regimens. With regard to lateral node dissection, a recent study showed that postoperative chemoradiotherapy was more effective in reducing the local recurrence rate than lateral node dissection. As for adjuvant chemotherapy, one randomized controlled trial showed that patients who received uracil and tegafur as adjuvant therapy had significantly prolonged relapse-free survival times and overall survival times. As well, one metaanalysis has shown the efficacy of oral uracil-tegafur as adjuvant chemotherapy for rectal cancer.

show abstract

“…The RTOG recently conducted a phase II randomized trial (RTOG 0247) comparing capecitabine, irinotecan, and radiation (arm 1) versus capecitabine, oxaliplatin, and radiation (arm 2) [ 29 ]. Due to an unexpectedly high grade 3 and 4 nonhematologic toxicity observed in both arms of the trial, accrual to RTOG 0247 was temporarily suspended.…”

Section: Anorectal Sphinctermentioning

confidence: 98%

The potential role of intensity modulated radiation therapy in the management of localized rectal cancer

Martin¹,

Nawaz²,

Kachnic

2008

Curr colorectal cancer rep

View full text Add to dashboard Cite

RTOG 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer

Cited by 13 publications

References 0 publications

Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients

Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients

Chemoradiotherapy and adjuvant chemotherapy for rectal cancer

The potential role of intensity modulated radiation therapy in the management of localized rectal cancer

Contact Info

Product

Resources

About